Clinical Trials
7 trialsNCT05923502 2023-10-23
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Ruijin Hospital
Not yet recruiting
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02391545 2023-09-28
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
Phase 1/2 Terminated
NCT04836832 2022-06-07
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02576275 2021-03-17
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
Phase 3 Withdrawn
NCT04342117 2021-03-17
REAL
SecuraBio
Terminated
NCT04707079 2021-01-13
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown